New International Research Explores Semaglutide’s Impact on Kidney Disease and Adipose Tissue

A significant international research collaboration is underway to investigate the complex relationship between adipose tissue, metabolism, and chronic kidney disease (CKD). Led by experts from the Universidad CEU Cardenal Herrera (CEU UCH) in Valencia, Spain, and the University of Alberta in Canada, the study focuses on how the medication semaglutide influences fat distribution in patients with impaired kidney function.

The project, titled Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKD, has secured international competitive funding of $125,000 from Novo Nordisk. By examining the biological mechanisms at play, the research team aims to determine how targeted treatments might mitigate the systemic damage often associated with obesity and metabolic dysfunction in patients with kidney disease.

Understanding the Role of Adipose Tissue and Adipocinas

While adipose tissue—commonly known as body fat—is essential for normal physiological function, its role changes significantly in the context of obesity. When adipose tissue expands excessively, it can produce proteins known as adipocinas. In a healthy state, these proteins support metabolic balance; however, in a state of chronic obesity, they can become markers of dysfunction.

This dysfunction often triggers chronic inflammation, which can cause progressive damage to vital organs, including the liver, heart, and kidneys. Researchers are particularly interested in how this inflammatory process accelerates the progression of cardiorenal and metabolic diseases.

The Potential of GLP-1 Receptor Agonists

The study evaluates the impact of GLP-1 receptor agonists, a class of medication that includes semaglutide. While these drugs have become a cornerstone in the management of type 2 diabetes and obesity, their specific effects on the remodeling of adipose tissue in patients with chronic kidney disease remain a critical area of study.

“Comprender estos mecanismos podría abrir nuevas vías terapéuticas para pacientes con enfermedad cardiorrenal y metabólica,” notes Dr. Luis D’Marco, lead investigator of the Research Group on Cardiorenal and Metabolic Diseases (IDECAM) at CEU UCH. By mapping these changes, the team hopes to identify how these medications might be used to provide more precise, personalized care for patients at high risk for cardiovascular and renal complications.

A Collaborative Clinical Approach

The research is currently being conducted through a multi-center approach. Initial phases of the study are taking place at the Mazankowski Alberta Heart Institute and the University of Alberta in Canada, where participants undergo advanced imaging, such as magnetic resonance imaging (MRI), to quantify fat accumulation in the heart, liver, and kidneys.

The study is expected to expand to Spain in the near future, incorporating a local cohort of patients via the CEU UCH. This international partnership underscores the importance of global cooperation in addressing the rising burden of metabolic diseases. The research team, which includes Dr. Luis D’Marco and Dr. Ana Checa, aims to translate these clinical findings into actionable strategies for long-term patient management.

Key Takeaways

• International Collaboration: Researchers from Spain and Canada are partnering to study the effects of semaglutide on adipose tissue in CKD patients.
• Focus on Mechanism: The study investigates how adipocinas contribute to inflammation and organ damage in patients with metabolic syndrome.
• Advanced Diagnostics: The project utilizes high-resolution imaging to track fat distribution changes in the liver, heart, and kidneys.
• Clinical Relevance: The findings could refine therapeutic approaches for patients living with both kidney disease and obesity.

Reference: University of Alberta. (2025). Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKD (ClinicalTrials.gov Identifier: NCT07187830).